Article
Biochemistry & Molecular Biology
Jie A. Wang, Yufeng Tang, Jingjing Zhang, Jie B. Wang, Mengjie Xiao, Guangping Lu, Jiahao Li, Qingbo Liu, Yuanfang Guo, Junlian Gu
Summary: In this study, the researchers investigated the role of the interaction between SIRT1 and SESN2 in DOX-induced cardiomyopathy. They found that SIRT1 deficiency aggravated cardiac damage, while the activation of SIRT1 had protective effects. Further studies revealed that SIRT1 reduced oxidative damage and apoptosis by attenuating the interaction between SESN2 and MDM2, thereby protecting the heart from DOX-induced toxicity.
Article
Pharmacology & Pharmacy
Chun Wang, Ling Hu, Shuang Guo, Qing Yao, Xiufen Liu, Bo Zhang, Xiangwen Meng, Xiaosong Yang
Summary: Myocardial apoptosis and necroptosis are key factors in doxorubicin-induced cardiotoxicity, while phosphocreatine (PCr) has been shown to have cardioprotective effects. PCr can alleviate myocardial cell death induced by DOX by increasing antioxidant activity, and activate the TAK1 signaling pathway to promote myocardial survival.
Article
Pharmacology & Pharmacy
Shanshan Wei, Wanjun Ma, Yuanying Yang, Taoli Sun, Chuanhao Jiang, Jian Liu, Bikui Zhang, Wenqun Li
Summary: This study found that trastuzumab (Tra) in combination with doxorubicin (Dox) leads to more severe cardiotoxicity compared to Dox alone in HER2-positive breast cancer treatment. The results demonstrate that Tra enhances Dox-induced cardiomyocyte apoptosis and cardiac dysfunction through the activation of the NLRP3 inflammasome.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Zi-Qi Liao, Yi-Nong Jiang, Zhuo-Lin Su, Hai-Lian Bi, Jia-Tian Li, Cheng-Lin Li, Xiao-Lei Yang, Ying Zhang, Xin Xie
Summary: This study investigated the role and mechanism of rutaecarpine (Rut) in doxorubicin (DOX)-induced cardiotoxicity. The results showed that Rut protected the heart from DOX-induced damage and increased the expression of antioxidant enzymes by activating the AKT pathway.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Hamidreza Dorostkar, Bibi Fatemeh Haghiralsadat, Mahdie Hemati, Fatemeh Safari, Azam Hassanpour, Seyed Morteza Naghib, Mohammad Hossein Roozbahani, M. R. Mozafari, Ali Moradi
Summary: Liposomal doxorubicin with favorable characteristics was designed and synthesized, and its physicochemical properties were investigated. The co-administration of liposomal doxorubicin with free doxorubicin and quercetin showed promising results in reducing cardiac enzymes, oxidative stress, and apoptosis, as well as improving antioxidant capacity in heart tissue.
Article
Food Science & Technology
Prasenjit Manna, Saikat Dewanjee, Swarnalata Joardar, Pratik Chakraborty, Hiranmoy Bhattacharya, Shrestha Bhanja, Chiranjib Bhattacharyya, Manas Bhowmik, Shovonlal Bhowmick, Achintya Saha, Joydeep Das, Parames C. Sil
Summary: This study revealed that CA has a protective effect against Dox-induced cardiotoxicity by suppressing oxidative stress and interfering with pathological signaling events. CA can potentially be used as an effective agent to alleviate Dox-induced cardiotoxicity in the future.
FOOD AND CHEMICAL TOXICOLOGY
(2022)
Article
Cell Biology
Yanyu Lu, Qianqian Min, Xiaoyan Zhao, Li Li, Guojun Zhao, Jianzeng Dong
Summary: Eupatilin has various biological activities, including anticancer, anti-inflammatory, antioxidant, neuroprotective, anti-allergic, and cardioprotective effects. This study aimed to investigate the protective effects of eupatilin on doxorubicin-induced cardiotoxicity. The results demonstrated that eupatilin attenuated inflammation, oxidative stress, and cardiomyocyte apoptosis, and improved doxorubicin-induced cardiac dysfunction by activating the PI3K-AKT signaling pathway. This study provides the first evidence for the therapeutic potential of eupatilin in doxorubicin-induced cardiotoxicity.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Yixuan Wan, Bo He, Dongyong Zhu, Lei Wang, Ruijue Huang, Jing Zhu, Chunhua Wang, Fabao Gao
Summary: The study found that NMN has a protective effect against DOX-induced cardiotoxicity by inhibiting inflammation, oxidative stress, and apoptosis to improve cardiac damage.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
(2021)
Review
Biochemistry & Molecular Biology
Chun-Yan Kong, Zhen Guo, Peng Song, Xin Zhang, Yu-Pei Yuan, Teng Teng, Ling Yan, Qi-Zhu Tang
Summary: This review provides a comprehensive overview of the mechanisms underlying the oxidative stress and cell death pathways induced by doxorubicin, which are the major factors responsible for the acute cardiotoxicity. The authors aim to offer new insights for researchers to discover potential therapeutic strategies to prevent or reverse doxorubicin-induced cardiotoxicity.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Food Science & Technology
Na Xu, Yi Lu, Xinmiao Yao, Rui Zhao, Zhebin Li, Jialei Li, Yinglei Zhang, Bo Li, Ye Zhou, Huifang Shen, Liqun Wang, Kaixin Chen, Li Yang, Shuwen Lu
Summary: NMCP-2 effectively protected against DOX-induced cardiotoxicity by counteracting oxidative stress and regulating the mitochondrial apoptosis pathway.
FOOD SCIENCE & NUTRITION
(2021)
Article
Nutrition & Dietetics
Guangping Lu, Qingbo Liu, Ting Gao, Jiahao Li, Jingjing Zhang, Ou Chen, Cong Cao, Min Mao, Mengjie Xiao, Xiaohui Zhang, Jie Wang, Yuanfang Guo, Yufeng Tang, Junlian Gu
Summary: This study aimed to explore the therapeutic potential and underlying mechanisms of the co-treatment of resveratrol (RES) and fibroblast growth factor 1 (FGF1) in a doxorubicin (DOX)-treated model. The results showed that RES could reduce the growth-promoting activity of FGF1 and exhibited a more powerful antioxidative capacity in a DOX-treated model, with cardioprotective action mediated through the SIRT1/NRF2 pathway.
Article
Medicine, Research & Experimental
Farshid Maleki, Mona Salimi, Reza Shirkoohi, Mohsen Rezaei
Summary: Transplantation of freshly isolated mitochondria into cardiomyocytes damaged by doxorubicin has been shown to significantly reduce the toxicity of doxorubicin on the heart and improve cell viability.
Article
Biochemistry & Molecular Biology
Xiaoping Wang, Qianbin Sun, Qianqian Jiang, Yanyan Jiang, Yawen Zhang, Jing Cao, Linghui Lu, Chun Li, Peng Wei, Qiyan Wang, Yong Wang
Summary: Cardiotoxicity is a major side effect of doxorubicin treatment, and cryptotanshinone may alleviate oxidative stress and apoptosis through the Akt-GSK-3 beta-mPTP pathway.
Article
Pharmacology & Pharmacy
Sara A. A. Al-Kenany, Nada N. N. Al-Shawi
Summary: This study found that cafestol can alleviate the cardiotoxic effects induced by doxorubicin through the activation of the Nrf2 pathway. Cafestol improved doxorubicin-induced cardiac injury, reduced levels of cardiac enzymes in the blood, increased antioxidant levels, suppressed inflammation, inhibited cardiac apoptosis, and regulated the expression of related genes.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Menglong Wang, Jishou Zhang, Mengmeng Zhao, Jianfang Liu, Jing Ye, Yao Xu, Zhen Wang, Di Ye, Dan Li, Jun Wan
Summary: This study demonstrates that RvD1 attenuates Dox-induced cardiac injury through improving cardiac function, reducing apoptosis and oxidative stress, and inhibiting inflammation and endoplasmic reticulum stress.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Alejandra Garcia-Garcia, Luis A. Alvarez-Sala-Walther, Hae-Young Lee, Cristina Sierra, Domingo Pascual-Figal, Miguel Camafort
Summary: The incidence and prevalence of heart failure are increasing globally, and management involves lifestyle changes and pharmacological treatments. Dietary recommendations for sodium and fluid restriction are expected to benefit HF patients, but there is currently a lack of clear evidence to support this.
KOREAN JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Surgery
Silvia Sanchez-Camara, Mari C. Asensio-Lopez, Mario Royo-Villanova, Fernando Soler, Ruben Jara-Rubio, Jose Francisco Garrido-Penalver, Eduardo Pinar, Alvaro Hernandez-Vicente, Jose Antonio Hurtado, Antonio Lax, Domingo A. Pascual-Figal
Summary: This study aims to determine the critical warm ischemia time based on in vivo biochemical changes. The findings suggest that there is a significant compromise in cellular function and viability 10 minutes after circulatory arrest, which is important for incorporating DCD into heart transplant programs.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Geriatrics & Gerontology
Miriam Diez-Diez, Marta Amoros-Perez, Jorge de la Barrera, Enrique Vazquez, Ana Quintas, Domingo A. Pascual-Figal, Ana Dopazo, Fatima Sanchez-Cabo, Monica E. Kleinman, Leslie B. Gordon, Valentin Fuster, Vicente Andres, Jose J. Fuster
Summary: Clonal hematopoiesis of indeterminate potential (CHIP), the presence of somatic mutations in cancer-related genes in blood cells without hematological cancer, is an important risk factor for age-related conditions, especially cardiovascular disease. It is unknown whether CHIP plays a role in premature aging syndromes. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition characterized by accelerated aging. This study investigated the prevalence of CHIP in HGPS patients and found that it is not frequent in HGPS, suggesting that it is unlikely to contribute to the pathophysiology of this accelerated aging syndrome.
Article
Cardiac & Cardiovascular Systems
Klaus K. Witte, Rolf Wachter, Michele Senni, Jan Belohlavek, Ewa Straburzynska-Migaj, Candida Fonseca, Eva Lonn, Adele Noe, Heike Schwende, Dmytro Butylin, YannTong Chiang, Domingo Pascual-Figal
Summary: The tolerability and dose up-titration patterns of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF) were comparable between patients with and without diabetes.
Article
Cardiac & Cardiovascular Systems
Phil McEwan, Cale Harrison, Rhona Binnie, Ruth D. Lewis, Alain Cohen-Solal, Lars H. Lund, Marcus Ohlsson, Stephan von Haehling, Josep Comin-Colet, Domingo A. Pascual-Figal, Sandra Wachter, Fabio Dorigotti, Antonio Ramirez de Arellano, Piotr Ponikowski, Ewa A. Jankowska
Summary: The study assessed the burden of disease and pharmacoeconomic implications of treating iron deficiency in patients with acute heart failure. The findings indicate that treatment with FCM can reduce hospitalizations and bed days, leading to savings in healthcare resources and improvement in quality of life for heart failure patients.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Antoni Bayes-Genis, Domingo Pascual-Figal
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Domingo Pascual-Figal, J. Luis Zamorano, Mar Domingo, Herminio Morillas, Julio Nunez, Marta Cobo Marcos, Alejandro Riquelme-Perez, Albert Teis, Enrique Santas, Cesar Caro-Martinez, Jose Manuel Pinilla, Jose F. Rodriguez-Palomares, David Dobarro, M. Alejandra Restrepo-Cordoba, J. Ramon Gonzalez-Juanatey, Antoni Bayes Genis
Summary: The DAPA-MODA trial showed that dapagliflozin administration in stable chronic heart failure patients leads to global reverse remodelling of cardiac structure, including reductions in left atrial volume index, improvement in left ventricular geometry, and decreased concentrations of NT-proBNP.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Review
Medicine, General & Internal
Jose Ramon Gonzalez-Juanatey, Josep Comin-Colet, Domingo Pascual Figal, Antoni Bayes-Genis, Jose Maria Cepeda, Jose M. Garcia-Pinilla, Antonio Garcia-Quintana, Luis Manzano, Jose Luis Zamorano
Summary: Heart failure requires a holistic approach that targets all neurohormonal systems, with vericiguat potentially playing a key role. The management of heart failure should be standardized at the local level, utilizing new technologies for remote monitoring and communication.
PATIENT PREFERENCE AND ADHERENCE
(2023)
Article
Medicine, Research & Experimental
Antonio Lax, Fernando Soler, Maria Josefa Fernandez del Palacio, Silvia Pascual-Oliver, Miriam Ruiz Ballester, Jose Javier Fuster, Domingo Pascual-Figal, Maria del Carmen Asensio-Lopez
Summary: This study investigated the role of the YY1/HDAC4/sST2 axis in doxorubicin-induced cardiotoxicity and found that blocking miR-106b can prevent this toxicity.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2023)
Article
Medicine, General & Internal
Lourdes Vicent, Jesus Alvarez-Garcia, Rafael Vazquez-Garcia, Jose R. Gonzalez-Juanatey, Miguel Rivera, Javier Segovia, Domingo Pascual-Figal, Ramon Bover, Fernando Worner, Francisco Fernandez-Aviles, Albert Ariza-Sole, Manuel Martinez-Selles
Summary: The aim of this study was to determine the prognostic impact of coronary artery disease (CAD) on heart failure with reduced ejection fraction (HFrEF) mortality and readmissions. A total of 583 patients with left ventricular ejection fraction <40% were included in the study, among which 266 had CAD and 137 had idiopathic dilated cardiomyopathy (DCM). The study found that one-year mortality and readmissions were similar between patients with CAD and idiopathic DCM, but patients with idiopathic DCM were more likely to receive a heart transplant.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Manuel Barreiro-Perez, Pablo Pastor Pueyo, Sergio Raposeiras-Roubin, Dolores Montero Corominas, Aitor Uribarri, Rocio Eiros Bachiller, Jose Rozado Castano, Luisa Garcia-Cuenllas Alvarez, Luis Serratosa Fernandez, Fernando Dominguez, Domingo Pascual Figal
Summary: This document, drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology in collaboration with the Spanish Agency for Medicines and Health Products (AEMPS), aims to summarize the knowledge acquired since the start of the SARS-CoV-2 pandemic regarding the diagnosis and treatment of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.
REVISTA ESPANOLA DE CARDIOLOGIA
(2023)
Article
Cardiac & Cardiovascular Systems
Manuel Veas Porlan, Antonio Tello-Montoliu, Cecilia Lopez-Garcia, Pablo Gil-Perez, Miriam Quintana-Giner, Raquel Lopez-Galvez, Jose Miguel Rivera-Caravaca, Francisco Marin, Domingo Pascual Figal
Summary: This study aimed to investigate the impact of chronic renal failure on the pharmacokinetics and pharmacodynamics of ticagrelor. It was found that patients with renal impairment showed higher levels of ticagrelor after 4 and 6 hours of use, but there were no significant differences in platelet inhibition.
IJC HEART & VASCULATURE
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Domingo Pascual-Figal, Jose Javier Fuster, Antoni Bayes-Genis
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Review
Medicine, General & Internal
Carlos Escobar, Domingo Pascual-Figal, Luis Manzano, Julio Nunez, Miguel Camafort
Summary: Based on recent evidence, SGLT2 inhibitors, specifically dapagliflozin, are recommended as first-line therapy for managing heart failure patients, irrespective of ejection fraction, to reduce the burden of heart failure. Studies have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total heart failure hospitalizations, and MACE in the entire spectrum of heart failure, with sustained benefits over time. Full implementation of dapagliflozin in clinical practice leads to a substantial reduction in hospitalizations for heart failure and death in real-life populations.
JOURNAL OF CLINICAL MEDICINE
(2023)
Correction
Biochemistry & Molecular Biology
Siew Chin Chan, Chih-Wei Tung, Chia-Wei Lin, Yun-Shiuan Tung, Po-Min Wu, Pei-Hsun Cheng, Chuan-Mu Chen, Shang-Hsun Yang
FREE RADICAL BIOLOGY AND MEDICINE
(2024)
Article
Biochemistry & Molecular Biology
Suyuan Liu, Meiling Tan, Jiangxue Cai, Chenxuan Li, Miaoxin Yang, Xiaoxiao Sun, Bin He
Summary: This study reveals that the antibiotic doxycycline effectively inhibits NLRP3 inflammasome activation by targeting mitochondrial translation and mtDNA synthesis, offering potential for the treatment of NLRP3-related diseases.
FREE RADICAL BIOLOGY AND MEDICINE
(2024)
Article
Biochemistry & Molecular Biology
Hao Liu, Nana Li, Ge Kuang, Xia Gong, Ting Wang, Jun Hu, Hui Du, Minxuan Zhong, Jiashi Guo, Yao Xie, Yang Xiang, Shengwang Wu, Yiling Yuan, Xinru Yin, Jingyuan Wan, Ke Li
Summary: Protectin D1 (PTD1) improves hepatic steatosis, inflammation and fibrosis in a NASH mouse model by inhibiting the activation of TLR4 downstream signaling pathway, possibly through upregulation of IRAK-M expression, suggesting a potential new treatment for NASH.
FREE RADICAL BIOLOGY AND MEDICINE
(2024)